Add Headings and they will appear in your table of contents.
£2.2m non dilutive EIC funding
Vector Bioscience has received a £2.2 million non-dilutive investment from the European Innovation Council “Transition Challenge”, designed to mature innovative technologies and catalyse their commercialisation.
Fast Start Innovation (IUK)
Vector works with enhanced and targeted treatments for cancer. The funds received for this grant will help Vector to strengthen the stability of the most efficient cancer treatment – macromolecules – in their platform technology. Thanks to their modular ‘plug-and-play’ materials, they develop a tailored platform technology based on specific porous materials called metal-organic frameworks.
This technology stems from more than 10 years of experience and know-how. With this grant, Vector will officially start the journey as a spin-out from the Department of Chemical Engineering and Biotechnology at the University of Cambridge.
Vector Bioscience works to have huge social impact not just by improving cancer treatment but also on the distribution and transport of treatments to rural areas or developing communities.
"The support from IUK means the translation of the work we have developed in the last 10 years toward more efficient and safer cancer therapies. We want to contribute to a world where we do not fear cancer”
Prof. David Fairen-Jimenez, CEO